Abstract
Nifedipine, a dihydropyridine calcium antagonist, improves endothelial function in patients with hypercholesterolaemia by enhancing nitric oxide (NO) activity, and increases endothelial NO bioavailability by antioxidant mechanisms. We administered a long-acting nifedipine formulation (controlled release (CR) nifedipine: 20 mg/day) to hypertensive patients for 6 months. There were no other changes of drug treatment during therapy with CR nifedipine. Clinical and biochemical data obtained before and after CR nifedipine administration were compared. All markers were measured by enzyme-linked immunosorbant assay. The levels of soluble markers (soluble CD40 ligand, soluble P-selectin, and soluble E-selectin), microparticles (MP) (platelet-derived MP, monocyte-derived MP, and endothelial cell-derived MP), and adiponectin differed between the control group and the hypertension group. The levels of these markers were also different in hypertensive patients with and without type 2 diabetes compared with the control group. In the hypertensive patients with type 2 diabetes, all markers except adiponectin decreased significantly after 3 months of CR nifedipine treatment. In contrast, markers were unchanged in the hypertensive patients without type 2 diabetes. Adiponectin was increased after 6 months of CR nifedipine treatment in hypertensive patients with type 2 diabetes. The effects of CR nifedipine on platelet/monocyte activation and adiponectin levels demonstrated in the present study indicate the potential effectiveness of calcium antagonist therapy for hypertensive patients with type 2 diabetes.
Similar content being viewed by others
References
Garcia Frade LJ, dela Calle H, Alava l, Navarro JL, Creighton LJ, Gaffney PJ . Diabetes as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. Thromb Res 1987; 47: 533–540.
Colwell JA, Halushka PV . Platelet function in diabetes. Br J Haematol 1980; 44: 521–526.
Sims PJ, Faioni EM, Wiedmer T, Shattil SJ . Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205–18212.
Nomura S, Suzuki M, Katsura K, Xie GL, Miyazaki Y, Miyake T et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes. Atherosclerosis 1995; 116: 235–240.
Nomura S . Function and clinical significance of platelet-derived microparticles. Int J Hematol 2001; 74: 397–404.
Nomura S, Kanazawa S, Fukuhara S . Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with type 2 diabetes mellitus. J Diabetes Complicat 2003; 17: 153–159.
Nomura S, Takahashi N, Inami N, Kajiura T, Yamada K, Nakamori H et al. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis 2004; 174: 329–335.
Ogata N, Imaizumi M, Nomura S, Shouzu A, Arich M, Matsuoka M et al. Increased levels of platelet-derived microparticles in patients with diabetic retinopathy. Diabetes Res Clin Pr 2005; 68: 193–201.
Drake TA, Ruf W, Morrissey JH, Edgington TS . Functional tissue factor is entirely surface expressed on lipopolysaccharide stimulated human blood monocytes and a constitutively tissue factor producing neoplastic cell line. J Cell Biol 1989; 109: 389–394.
Osnes LTN, Westvik AB, Kieruf P . Procoagulant and profibrinolytic activities of cryopreserved human monocytes. Thromb Res 1994; 76: 373–383.
Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Esshewegw V et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 1994; 153: 3245–3255.
Omoto S, Nomura S, Shouzu A, Nishikawa M, Fukuhara S, Iwasaka T . Detection of monocyte-derived microparticles in patients with type II diabetes mellitus. Diabetologia 2002; 45: 550–555.
Nomura S, Kanazawa S, Fukuhara S . Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens 2002; 16: 539–547.
Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T . Benidipine improves oxidized LDL-dependent monocyte and endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 2005; 19: 551–557.
Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T, Fukuhara S . Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes. Clin Appl Thromb Hemost 2004; 10: 205–215.
Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T . Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006; 117: 385–392.
Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296–1301.
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79–83.
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetes patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595–1599.
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930–1935.
Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein, adiponectin. Circulation 1999; 100: 2473–2476.
Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ . Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021–45026.
Hattori Y, Suzuki M, Hattori S, Kasai K . Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003; 46: 1543–1549.
Schulze MB, Rimm EB, Shai I, Ritai N, Hu FB . Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004; 27: 1680–1687.
Verhaar MC, Honing HL, van Dam T, Zwart M, Koomans HA, Kastelein JJ et al. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res 1999; 42: 752–760.
Berkels R, Eqink G, Marsen TA, Bartels H, Roesen R, Klaus W . Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001; 37: 240–245.
The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group Report on Hypertension in diabetes. Hypertension 1994; 23: 145–158.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert commitee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183–1197.
Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM et al. Microalbuminuria and coronary heart disease in non-insulin- dependent diabetes: an incidence study. Diabetes 1998; 47: 1786–1792.
Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–945.
Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452–458.
Kawata T, Hashimoto S, Koike T . Diversity in the renal hemodynamic effects of dihydropyridine calcium blockers in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1997; 30: 431–436.
Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237–1245.
Lupo E, Locher R, Weisser B, Vetter W . In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with α-tocopherol. Biochem Biophys Res Commun 1994; 203: 1803–1808.
Berkels R, Bertsch A, Breitenbach T . The calcium antagonist nifedipine stimulates endothelial NO release in therapeutical concentrations. Pharm Pharmcol Lett 1996; 2: 75–78.
Kitakaze M, Asanuma H, Takashima S, Minamino T, Ueda Y, Sakata Y et al. Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. Circulation 2000; 101: 311–317.
Nyrop M, Zweifer AJ . Platelet aggregation in hypertension and the effects of antihypertensive treatment. J Hypertens 1988; 6: 263–269.
Ross R . Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115–126.
Hjemdahl P, Larsson PT, Wallen NH . Effects of stress and β-blockade on platelet function. Circulation 1991; 84 (Suppl VI): VI-44–VI-61.
Sinzinger H, Virgolini I, Rauscha F, Fitscha P, O'Grady J . Isradipine improves platelet function in hypertensives. Eur J Clin Pharmacol 1992; 42: 43–46.
Tomoda F, Takata M, Kagitani S, Kinuno H, Yasumoto K, Tomita S et al. Effects of a novel calcium antagonist, benidipine hydrochloride, on platelet responsiveness to mental stress in patients with essential hypertension. J Cardiovasc Pharmacol 1999; 34: 248–253.
Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–1762.
Mohlig M, Wegewitz U, Osterhoff M, Isken F, Ristow M, Pfeiffer AF et al. Insulin decreases human plasma adiponectin levels. Horm Metab Res 2002; 34: 655–658.
Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T . Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2005; 115: 277–285.
Taddei S, Virdis A, Ghiadomi L, Maganda A, Favilla S, Pompella A et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001; 37: 943–948.
Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T . 5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes. Blood Coag Fibrinolys 2005; 16: 423–428.
Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW . Retardation of aniographic progression of coronary artery disease by nifedipine (INTACT). Lancet 1990; 335: 1109–1113.
Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82: 1940–1953.
Acknowledgements
This study was partly supported by a grant from the Japan Foundation of Neuropsychiatry and Hematology Research, a Research Grant for Advanced Medical Care from the Ministry of Health and Welfare of Japan, and a Grant (13670760 to SN) from the Ministry of Education, Science and Culture of Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nomura, S., Inami, N., Kimura, Y. et al. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 21, 38–44 (2007). https://doi.org/10.1038/sj.jhh.1002100
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1002100
- Springer Nature Limited
Keywords
This article is cited by
-
Extracellular Vesicles in Essential Hypertension: Hidden Messengers
Current Hypertension Reports (2020)
-
Clinical roles of calcium channel blockers in ischemic heart diseases
Hypertension Research (2017)
-
The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles
Cardiovascular Drugs and Therapy (2017)
-
Innovative biomarkers for predicting type 2 diabetes mellitus: relevance to dietary management of frailty in older adults
Biogerontology (2016)
-
Clinical significance of procoagulant microparticles
Journal of Intensive Care (2015)